期刊
BRITISH JOURNAL OF SURGERY
卷 105, 期 2, 页码 E48-E60出版社
WILEY
DOI: 10.1002/bjs.10726
关键词
-
类别
资金
- Cold Spring Harbor Cancer Center Support Grant [P30CA045508-29]
- European Union subsidy programme Interreg as part of the OncoCare project Euregio Maas Rijn
- Lustgarten Foundation
- Cold Spring Harbor Laboratory Association
- National Institutes of Health [5P30CA45508-29, 5P50CA101955-07, 1U10CA180944-04, 5U01CA168409-5, 1R01CA18813401, 1R01CA190092-04]
- V Foundation
- Stand Up to Cancer [AACRPS09]
- Integrated Translational Science Center [5U10CA180944-04]
- NATIONAL CANCER INSTITUTE [U10CA180944, R01CA190092, R01CA188134, P30CA045508] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK089502] Funding Source: NIH RePORTER
Background: The prognosis of patients with different gastrointestinal cancers varies widely. Despite advances in treatment strategies, such as extensive resections and the addition of new drugs to chemotherapy regimens, conventional treatment strategies have failed to improve survival for many tumours. Although promising, the clinical application of molecularly guided personalized treatment has proven to be challenging. This narrative review focuses on the personalization of cancer therapy using patient-derived three-dimensional 'organoid' models. Methods: A PubMed search was conducted to identify relevant articles. An overview of the literature and published protocols is presented, and the implications of these models for patients with cancer, surgeons and oncologists are explained. Results: Organoid culture methods have been established for healthy and diseased tissues from oesophagus, stomach, intestine, pancreas, bile duct and liver. Because organoids can be generated with high efficiency and speed from fine-needle aspirations, biopsies or resection specimens, they can serve as a personal cancer model. Personalized treatment could become a more standard practice by using these cell cultures for extensive molecular diagnosis and drug screening. Drug sensitivity assays can give a clinically actionable sensitivity profile of a patient's tumour. However, the predictive capability of organoid drug screening has not been evaluated in prospective clinical trials. Conclusion: High-throughput drug screening on organoids, combined with next-generation sequencing, proteomic analysis and other state-of-the-art molecular diagnostic methods, can shape cancer treatment to become more effective with fewer side-effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据